Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

39.52 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
30 31 Next >
Roche's Long-Time CEO Passes Baton, Higher Diagnostics, Medicine Sales Lift 1H Sales & Profit
Via Benzinga
Novartis Posts Mixed Q2 Earnings, Expects Improved Earnings At Sandoz
Via Benzinga
Mortgage Financiers & Crypto Securities Reclaim Their Spots As Most Actively Traded Securities On OTC Markets In June
Reflecting the expected conditions of a bear market, many of the world’s indices saw a decrease in price throughout June. 
Via Benzinga
Roche Launches Dual Antigen & Antibody Hepatitis C Diagnostic Test
Via Benzinga
New Two-Year Data Confirm Genentech’s Vabysmo Improves Vision With Fewer Treatments for People With Wet Age-Related Macular Degeneration
From Genentech
Via Business Wire
Why 'Covid Fatigue' Isn't Enough To Keep BioNTech Down; Shares Surge On Upgrade
BioNTech won an upgrade Wednesday. Here's what one analyst expects to drive growth. 
Via Investor's Business Daily
New Data Reinforce Favorable Safety, Efficacy Of Roche's Hemlibra For Hemophilia A
Via Benzinga
The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
New Data From Phase III HAVEN 6 Study Reinforce Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A
From Genentech
Via Business Wire
Merck Reportedly Eyes $40 Billion Seagen Tie-Up; Will The Deal Save Biotech?
Two major cancer players are reportedly closing in on a massive merger. 
Via Investor's Business Daily
Is Merck Stock A Buy Amid Reports It Could Buy Seagen For $40 Billion?
Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now? 
Via Investor's Business Daily
10 Most Traded OTC Stocks In June: Where Do Danone, Adidas And Grayscale Bitcoin Trust Rank?
The month of June saw $45.2 billion in trading volume for stocks that trade on the OTCQK and OTCQB. While some of the stocks that trade over-the-counter are considered penny stocks based on their share... 
Via Benzinga
Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial
Via Benzinga
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
FDA Grants Priority Review to Genentech’s Mosunetuzumab for People With Relapsed or Refractory Follicular Lymphoma
From Genentech
Via Business Wire
Celldex Therapeutics Skids As It Takes On A Blockbuster Roche, Novartis Drug
The study was in 26 patients with chronic hives that don't respond to antihistamines. 
Via Investor's Business Daily
The OTC Markets' Most-Active Securities Embrace International Operators As Volatility Envelops Markets In May
Reflecting the world’s uncertainty about the U.S. economy, the market’s major indices saw incredible volatility in May. 
Via Benzinga
Why Mereo BioPharma Shares Are Jumping Today
Via Benzinga
Roche's Alzheimer's Failures Keep Piling Up; Can The Stock Recover?
Roche hoped to prevent Alzheimer's disease in patients with a genetic defect. 
Via Investor's Business Daily
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Roche-AC Immune's Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer's Patients
Via Benzinga
Genentech Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease
From Genentech
Via Business Wire
5 Cash-Cow Stocks to Buy for a Turbulent Market
These are five of the best cash-cow stocks and ETFs to buy that could help grow your investment portfolio in the second half of 2022 
Via InvestorPlace
Genentech Announces Positive Data from Broad Blood Cancer Portfolio at European Hematology Association Annual Meeting
From Genentech
Via Business Wire
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Early Data Shows BioNTech's Personalized Therapy Safe In Pancreatic Cancer Patients
Via Benzinga
Diagnostic Companies Focus On Monkeypox Tests Following Outbreak; Experts Do Not Count It As Next COVID Yet
Diagnostic companies aggressively developed tests for monkeypox as governments struggle to trace the world's first major viral infection outbreak beyond Africa, 
Via Benzinga
FDA Approves Genentech’s Evrysdi (risdiplam) for Use in Babies Under Two Months With Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
New Pivotal Data Demonstrate Clinical Benefit of Genentech’s Glofitamab, a Potential First-in-Class Bispecific Antibody for People With Aggressive Lymphoma
From Genentech
Via Business Wire
One-Trick Pony Boan Biotech Files for Hong Kong IPO Into Tough Market
Key Takeaways: Boan Biotechnology sells only one product so far and is facing stiff competition from other similar drugs Luye Pharma bought Boan in 2020 and is taking it public... 
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 22
...
30 31 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.